Current and Future Developments in the Treatment of CD30+ Lymphomas
CD30 is a cell membrane protein expressed on the surface of a range of lymphomas, which has important diagnostic, pathogenic, and prognostic roles. The most common CD30+ lymphomas are Hodgkin’s lymphoma (HL) and anaplastic large cell lymphoma (ALCL), but other types of lymphoma also express CD30, al...
Main Authors: | Lena Specht, Christian Gisselbrecht |
---|---|
Format: | Article |
Language: | English |
Published: |
European Medical Journal
2015-11-01
|
Series: | European Medical Journal Oncology |
Subjects: | |
Online Access: | http://emjreviews.com/wp-content/uploads/Current-and-Future-Developments-in-the-Treatment-of-CD30-Lymphomas.pdf |
Similar Items
-
Role of ADAM10 as a CD30 Sheddase in Classical Hodgkin Lymphoma
by: Hinrich P. Hansen, et al.
Published: (2020-03-01) -
CD19 and CD30 CAR T-Cell Immunotherapy for High-Risk Classical Hodgkin’s Lymphoma
by: YuanBo Xue, et al.
Published: (2021-02-01) -
THE STANDARD OF CARE IN RELAPSED REFRACTORY CD30+ LYMPHOMA
by: Martin Hutchings
Published: (2014-07-01) -
The Evolving Role of Brentuximab Vedotin in Classical Hodgkin Lymphoma
by: Lai C, et al.
Published: (2019-12-01) -
Development of a Bispecific Antibody Targeting CD30 and CD137 on Hodgkin and Reed-Sternberg Cells
by: Sakthi Rajendran, et al.
Published: (2019-09-01)